Ascendis Pharma (ASND) stock rocketed Monday on promising test results for a growth treatment that could rival BioMarin Pharmaceutical's (BMRN) approved drug, Voxzogo.
Ascendis tested its drug, dubbed TransCon CNP, in children ages 2 to 11 with achondroplasia. In this genetic condition, an abnormal protein causes slow growth. Children who received TransCon CNP for a year grew an average 5.89 centimeters, compared to 4.41 centimeters for placebo recipients.
Ascendis Pharma's results look competitive with BioMarin's Voxzogo, Leerink Partners analyst Joseph Schwartz said in a report.
"Acknowledging the perils of cross-trial comparisons, it appears that TransCon CNP data are competitive vs. the one approved product," he said. "Moreover, considering TransCon CNP is a once-weekly injection vs. once-daily for Voxzogo, we see this becoming a meaningful product for Ascendis," he said.
https://www.investors.com/news/technology/ascendis-pharma-stock-biomarin-voxzogo/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.